About Landos Biopharma
Landos Biopharma is a company based in Blacksburg (United States) founded in 2016 was acquired by AbbVie in March 2024.. Landos Biopharma has raised $70.26 million across 3 funding rounds from investors including AbbVie, HHS and RTW Investments. Landos Biopharma offers products and services including NX-13 and AbbVie Pipeline Assets. Landos Biopharma operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Moderna, Denali Therapeutics and C4 Therapeutics, among others.
- Headquarter Blacksburg, United States
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Abbvie Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Landos Biopharma
Landos Biopharma offers a comprehensive portfolio of products and services, including NX-13 and AbbVie Pipeline Assets. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Oral NLRX1 agonist for treating ulcerative colitis and Crohn's disease.
Develops medicines for immunology and oncology through acquisitions.
Unlock access to complete
Funding Insights of Landos Biopharma
Landos Biopharma has successfully raised a total of $70.26M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $1.23 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Grant — $1.2M
-
First Round
First Round
(21 Sep 2017)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2020 | Amount | Grant - Landos Biopharma | Valuation |
investors |
|
| Aug, 2019 | Amount | Series B - Landos Biopharma | Valuation | RTW Investments , Perceptive Advisors | |
| Sep, 2017 | Amount | Series A - Landos Biopharma | Valuation | Perceptive Advisors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Landos Biopharma
Landos Biopharma has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include AbbVie, HHS and RTW Investments. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life Sciences focused VC firm investing in the US
|
Founded Year | Domain | Location | |
|
Health-tech companies are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
PE firm investing in the US
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Landos Biopharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Landos Biopharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Landos Biopharma Comparisons
Competitors of Landos Biopharma
Landos Biopharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Moderna, Denali Therapeutics and C4 Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Landos Biopharma
Frequently Asked Questions about Landos Biopharma
When was Landos Biopharma founded?
Landos Biopharma was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Where is Landos Biopharma located?
Landos Biopharma is headquartered in Blacksburg, United States. It is registered at Blacksburg, Virginia, United States.
Is Landos Biopharma a funded company?
Landos Biopharma is a funded company, having raised a total of $70.26M across 3 funding rounds to date. The company's 1st funding round was a Series A of $10M, raised on Sep 21, 2017.
What does Landos Biopharma do?
Developer of small molecule therapeutics for autoimmune diseases. The company has drug candidates which include BT-104 and BT-111 for the treatment of nonalcoholic steatohepatitis, type 1 diabetes, systemic lupus erythematosus, and rheumatoid arthritis, NX-66 and NX-73 are NLRX1 pathway agonist for the treatment of multiple sclerosis, Alzheimers disease, asthma, and COPD The candidate. PX-69 is a PLXDC2 pathway agonist for the treatment of diabetic nephropathy and rheumatoid arthritis.
Who are the top competitors of Landos Biopharma?
Landos Biopharma's top competitors include Moderna, Jazz Pharmaceuticals and C4 Therapeutics.
What products or services does Landos Biopharma offer?
Landos Biopharma offers NX-13 and AbbVie Pipeline Assets.
Who are Landos Biopharma's investors?
Landos Biopharma has 6 investors. Key investors include AbbVie, HHS, RTW Investments, Perceptive Advisors, and PBM Capital.